Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Free Report) has earned a consensus recommendation of “Buy” from the ten analysts that are presently covering the firm, Marketbeat reports. Nine investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $20.43.
A number of research firms have issued reports on LRMR. Oppenheimer began coverage on Larimar Therapeutics in a report on Wednesday, October 16th. They issued an “outperform” rating and a $26.00 target price on the stock. Baird R W raised Larimar Therapeutics to a “strong-buy” rating in a report on Wednesday, September 4th. Wedbush started coverage on Larimar Therapeutics in a report on Thursday, October 3rd. They set an “outperform” rating and a $22.00 price objective on the stock. Robert W. Baird started coverage on Larimar Therapeutics in a report on Wednesday, September 4th. They set an “outperform” rating and a $16.00 price objective on the stock. Finally, HC Wainwright started coverage on Larimar Therapeutics in a report on Wednesday, October 2nd. They set a “buy” rating and a $15.00 price objective on the stock.
Read Our Latest Stock Report on Larimar Therapeutics
Institutional Trading of Larimar Therapeutics
Larimar Therapeutics Stock Down 2.4 %
LRMR opened at $7.35 on Thursday. The firm has a market capitalization of $468.94 million, a P/E ratio of -7.58 and a beta of 0.98. The stock’s 50 day moving average price is $7.31 and its two-hundred day moving average price is $7.77. Larimar Therapeutics has a 12-month low of $2.18 and a 12-month high of $13.68.
Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) last released its earnings results on Wednesday, August 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.02). As a group, analysts anticipate that Larimar Therapeutics will post -1.38 earnings per share for the current year.
About Larimar Therapeutics
Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.
Further Reading
- Five stocks we like better than Larimar Therapeutics
- How to Calculate Options Profits
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- What to Know About Investing in Penny Stocks
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Stock Market Upgrades: What Are They?
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.